A Slovak biotechnology company producing clonal monospecific rabbit antibodies for clinical pathology and research applications is seeking partners for distributing its products. The company has 140 ready to use antibodies already on the market and these can be distributed to the clients right away. Also, there is a capacity for new partners available for the development of a new antibodies and for the use of company’s proteomic services in a form of services or manufacturing agreements.
The Slovak company established in 2007 is looking for business partners to conclude a distribution services agreement, services agreement or manufacturing agreement. The company is offering its rabbit clonal monospecific antibodies that can be used for the following applications: immunohistochemistry (IHC) on paraffin sections of the tissue biopsies, western blot, immunocytochemistry (ICC), immunoprecipitation (IP) and flow cytometry (FC) on blood and other body fluids samples. Its detection system is dual, mouse/rabbit, horseradish peroxidase (HRP) labelled micropolymer based secondary antibody conjugate, designed for applications in immunohistochemistry. It detects separately rabbit or mouse immunoglobulins, or both bound to an antigen presented in the tissue or cell samples. Its proteomic services can be used for protein identification and characterisation studies very helpful in characterisation and diagnosis of immune system related, (neuro) degenerative disease, diabetes and cancer. Company is offering capacities of its fully equipped proteomic services laboratory or for development of the new antibodies, or for involvement in human diseases characterisation, diagnosis, potentially a treatment. Based on distribution services agreement the antibodies and detection system could be distributed to potential new clients right away. Company has also capacities for design, development and production of new antibodies, based on specifications by a partner respectively based on services or manufacturing agreements.
Innovations and advantages
All the products are produced locally, using unique technology, (propriety of the company) for design and production. This technology enables the design of antibodies even to complicated epitopes, eliminates some disadvantages of classical, hybridoma based technologies and produces highly specific, fully glycosylated antibodies. The company´s products have usually higher avidity and affinity compared to others, enabling larger dilutions. The technology was proven to be effective in production of more than 140 antibodies already on the market. Company’s products are currently distributed in the UK, France, the USA, Vietnam, Mexico, Turkey, Japan, just to mention a few, with overwhelmingly positive feedbacks. The main advantages of its products are: instant availability (company is the manufacturer and is stocking all of them in place), short delivery terms and large price flexibility. Presence of the well-equipped proteomic laboratory on the premises is a big advantage, enabling combination of know-how and production capacities in the same unit.
06001002 Clinical Research, Trials
06001003 Cytology, Cancerology, Oncology
06001005 Diagnostics, Diagnosis
06001012 Medical Research
Market application codes
05001001 Diagnostic services
05001002 In-vitro diagnostics
05001003 Differential diagnosis
05001005 Molecular diagnosis
05001007 Other diagnostic
Intellectual property rights
Comments, number and date of patent
The technology and know-how was developed after more than 30 years of active experience in basic and applied research laboratories in Europe, USA and Canada, and is an exclusive property of the company.
Type of partner sought
Type of partners: - Distributing partner - Partner in developing new products - Partner helping to finance R&D and production of a new product Company has 140 ready to use antibodies already on the market, and these can be distributed to the clients right away. Also, there is a capacity for new partners available for the development of a new antibodies and for the use of company’s proteomic services for human diseases characterisation, development of diagnostic tools and potentially for the treatment in the form of services or manufacturing agreement.